Skip to content

Crinetics Pharmaceuticals CRNX Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five

Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five at other companies

KKR & Co. logo
KKR & Co.KKR
$11.53B+2.4%
The Travelers Companies logo
The Travelers CompaniesTRV
$20.76B-9.6%
State Street logo
State StreetSTT
$39.88B+21.1%
3M logo
3MMMM
$121M+152%
KKR & Co. logo
KKR & Co.KKR
$13.69B+28.0%
Duke Energy logo
Duke EnergyDUK
$896M+14.1%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$3.79B+21.9%

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Crinetics Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five?
Crinetics Pharmaceuticals (CRNX) reported debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five of $458.19M in Q1 2026.